• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Mobocertinib is a tolerable and possible treatment option for patients with EGFR exon 20 insertion mutated advanced non-small-cell lung cancer

byKassandra McFarlaneandSze Wah Samuel Chan
October 18, 2021
in Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Overall response rate was 28% and 35% in the platinum pretreated cohort (PPP) and 25% and 32% in the EXCLAIM cohort (independent review committee and investigator assessment percentages, respectively).

2. Progression free survival was 7.3 months in both the PPP and EXCLAIM cohort, while overall survival was 2 years in the PPP group and not reached in the EXCLAIM group.

Evidence Rating Level: 2 (Good)

Study Rundown: EGFR exon 20 insertion (EGFRex20ins) mutations are a rare form of non-small cell lung cancer (NSCLC). First line treatment is platinum-based chemotherapy, but the disease progresses for most patients within 6 months. The use of non-specific EGFR tyrosine kinase inhibitors (TKIs) has minimal effectivity on this particular mutation of NSCLC. However, mobocertinib, a TKI targeting the EGFRex20ins mutation, has shown encouraging results in previous phase 1/2 clinical trials. This report details the outcomes of daily mobocertinib on objective response rate (ORR; assessed via computed tomography (CT) or magnetic resonance imaging (MRI)), progression free survival (PFS), overall survival (OS), and safety in patients with EGFRex20ins mutated NSCLC. Results are presented for two cohorts: those who had been pretreated with platinum-based chemotherapy (PPP cohort) and those previously treated with systemic therapy (EXCLAIM cohort). In the PPP cohort, ORR was 28% and 35% by independent review committee (IRC) and investigator assessment, respectively. PFS was 7.3 months and median OS was 2 years. ORR in the EXCLAIM cohort was 25% and 32% by IRC and investigator assessment, respectively. PFS was 7.3 months, while median OS was not reached. Safety was assessed by the extent and tolerability of adverse effects (AEs) and the most common of any severity in both groups were rash and diarrhea. Diarrhea was the most common severe AE. Skin and gastrointestinal AEs were mainly mild, and all AE were adequately managed by supportive treatment, modifying dosage, or discontinuing mobocertinib. Only 17% of the PPP cohort and 10% of the EXCLAIM cohort stopped mobocertinib due to AEs. Limitations of this study include its status as a non-randomized trial with no control arm. As well, not all tumour tissues obtained were adequate samples for assessment and not all EGFRex20ins mutations were detectable. Finally, this study may not be applicable to evaluate response rates in patient populations with active brain metastases as they were excluded. Overall, mobocertinib appears to be a potential treatment option with a decent safety profile for use in patients with EGFRex20ins mutated NSCLCs.

Click to read the study in JAMA Oncology

Relevant Reading: Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

In-Depth [prospective cohort]: This cohort expansion from the phase 1/2 nonrandomized clinical trial included 114 patients who were pretreated with platinum therapy (PPP cohort) and 96 patients who had been previously treated with 160 mg daily mobocertinib (EXCLAIM cohort) for EGFRex20ins mutated NSCLC. The effect of 160 mg mobocertinib administration once daily on objective response rate (ORR), progression free survival (PFS), overall survival (OS), and safety was reported. Treatment cycles were 28 days, and patients received 160 mg of oral mobocertinib daily until the disease progressed, they experienced severe adverse events (AEs), or met other specified study-cessation criteria. Response to treatment was assessed via CT or MRI of the brain, chest, abdomen, and pelvis. In the PPP cohort, the ORR was 28% (95% confidence interval (CI), 20-37%) and 35% (95% CI, 26-45%) by IRC and investigator assessment, respectively. PFS was 7.3 months (95% CI, 5.5-9.2 months) and median OS was 2 years (24 months) (95% CI, 14.6-28.8 months). In the EXCLAIM cohort, the ORR was 25% (95% CI, 17-35%) and 32% (95% CI, 23-43%) by IRC and investigator assessment. PFS was 7.3 months (95% CI, 5.5-9.1 months), while median OS was not reached. Within both groups, the most common AEs of any severity were rash and diarrhea. The most common severe AE was diarrhea, and most of the skin and gastrointestinal (GI) AEs were relatively mild. All AEs were manageable either by supportive treatment, and modifying or discontinuing mobocertinib. Treatment was discontinued due to AEs in 17% of the PPP cohort and in 10% of the EXCLAIM cohort.

RELATED REPORTS

#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

Toripalimab addition to chemotherapy showed improved survival in advanced stage non-small-cell lung cancer

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: eGFREGFR tyrosine kinase inhibitorsnon-small cell lung cancer (NSCLC)
Previous Post

Monthly subsidy increased purchase of fresh fruits and vegetables in Supplemental Nutrition Assistance Program beneficiaries

Next Post

Ethnic differences in pediatric opioid prescriptions following long bone fractures declined over time

RelatedReports

#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease
StudyGraphics

#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease

December 6, 2022
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

November 30, 2022
Patient Basics: Squamous Cell Carcinoma of the Lung
Oncology

Toripalimab addition to chemotherapy showed improved survival in advanced stage non-small-cell lung cancer

October 17, 2022
#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients
StudyGraphics

#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients

September 28, 2022
Next Post
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Ethnic differences in pediatric opioid prescriptions following long bone fractures declined over time

Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Increased seizures during rewarming of neonates associated with risk of abnormal neurodevelopmental outcomes at 2-year follow-up

Your Blonde Hair Needs These Purple Shampoos, For Sure

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options